The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Luchman, H Artee ^a   Benediktsson, Hallgrimur ^b   Villemaire, Michelle L ^a   Peterson, Alan C ^c   Jirik, Frank R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TAMOXIFEN; 4 HYDROXYTAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANDROGEN BINDING PROTEIN; BETA ARRESTIN; DRUG DERIVATIVE; INTEGRASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN S6; PTEN PROTEIN, MOUSE; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE DELETION; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; ANIMAL; CANCER INVASION; CROSS BREEDING; DISEASE COURSE; ENZYMOLOGY; EPITHELIUM; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PRECANCER; PROSTATE TUMOR; RAT; TIME; TUMOR SUPPRESSOR GENE; UPREGULATION;

MURINAE; MUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGEN-BINDING PROTEIN; ANIMALS; APOPTOSIS; ARRESTINS; CELL PROLIFERATION; CROSSES, GENETIC; DISEASE PROGRESSION; EPITHELIUM; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; INTEGRASES; MALE; MICE; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RATS; RIBOSOMAL PROTEIN S6; TAMOXIFEN; TIME FACTORS; UP-REGULATION;

EID: 58049195703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003940     Document Type: Article

References (31)

1. Tomlins SA, Rubin MA, Chinnaiyan AM (2006) Integrative biology of prostate cancer progression. Annu Rev Pathol 1: 243-271.
2. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J (2005) Molecular pathology of prostate cancer. J Clin Pathol 58: 673-684.
3. Tomlins SA, Rubin MA, Chinnaiyan AM (2006) Integrative Biology of prostate cancer progression. Annual Review of Pathology:Mechanisms of Disease 1: 243-271.
4. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209-221.
5. Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, et al. (2004) Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci U S A 101: 1725-1730.
6. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, et al. (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65: 5730-5739.
7. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1: E59.
8. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 100: 7841-7846.
9. Hawkins PT, Anderson KE, Davidson K, Stephens LR (2006) Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 34: 647-662.
10. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346 Pt 3: 561-576.
11. Chow LM, Baker SJ (2006) PTEN function in normal and neoplastic growth. Cancer Lett 241: 184-196.
12. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
13. Carver BS, Pandolfi PP (2006) Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 12: 5305-5311.
14. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, et al. (1994) Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 269: 31763-31769.
15. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92: 3439-3443.
16. Yan Y, Sheppard PC, Kasper S, Lin L, Hoare S, et al. (1997) Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 32: 129-139.
17. Wu X, Wu J, Huang J, Powell WC, Zhang J, et al. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101: 61-69.
18. Kasper S (2005) Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 94: 279-297.
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
20. Abate-Shen C, Shen MM (2002) Mouse models of prostate carcinogenesis. Trends Genet 18: S1-5.
21. Luchman HA, Friedman HC, Villemaire ML, Peterson AC, Jirik FR (2008) Temporally controlled prostate epithelium-specific gene alterations. Genesis 46: 229-234.
22. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, et al. (1994) The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 8: 230-239.
23. Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, et al. (1999) Selective activation of the probasin androgen-responsive region by steroid hormones. J Mol Endocrinol 22: 313-325.
24. Zhang J, Thomas TZ, Kasper S, Matusik RJ (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141: 4698-4710.
25. Maddison LA, Nahm H, DeMayo F, Greenberg NM (2000) Prostate specific expression of Cre recombinase in transgenic mice. Genesis 26: 154-156.
26. Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, et al. (2008) Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci U S A 105: 2521-2526.
27. Thomson AA, Cunha GR (1999) Prostatic growth and development are regulated by FGF10. Development 126: 3693-3701.
28. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, et al. (2007) Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12: 572-585.
29. Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133: 403-414.
30. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
31. Singh J, Zhu Q, Handelsman DJ (1999) Stereological evaluation of mouse prostate development. J Androl 20: 251-258.